Navigation Links
adams & weber GmbH and Ekahau Install a Location and Emergency Call System for Dementia Patients and Staff at Josef-Ecker-Stift in Neuwied
Date:1/30/2013

RESTON, Virginia, January 30, 2013 /PRNewswire/ --

The adams & weber GmbH company, an experienced IT-system house in the Rhine-Mosel region, collaborated with  Ekahau, the worldwide leader in Real-Time Location Systems (RTLS), to install a WLAN-based locating and emergency call system at Josef-Ecker-Stift, a senior-citizens home and nursing facility in Neuwied, Germany. The system monitors the movements of the home's residents and, whenever danger threatens, it enables the care staff to speedily intervene and thus prevent accidents.

     (Logo: http://photos.prnewswire.com/prnh/20120504/EkahauLogo)

Josef-Ecker-Stift in Neuwied places great importance on giving its residents - despite their dementia -the privilege to move freely and independently throughout the building, while simultaneously protecting them against potential accidents and dangers, for example, falling in a stairwell. Josef-Ecker-Stift's director Siegfried Hartinger therefore sought a location system that would assist the home's care staff with their work and speedily notify them whenever danger threatens. He opted for Ekahau's RTLS Real-time Location System. Ekahau collaborated with the adams & weber GmbH to install the emergency-call and location system at Josef-Ecker-Stift toward the end of 2012.

The system monitors the movements of the home's residents and indicates the direction in which each person is heading. It also monitors residents with limited mobility, for example, people who rely on walkers. The system locates the Ekahau wristband tags which the residents wear 24-hours a day, and continually notifies the care staff of each resident's momentary location. This makes the caregivers' work easier because it
'/>"/>

SOURCE Ekahau Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Chiltern Welcomes Drs. Dieter Seitz-Tutter And Alexandra Adams
2. Generex Provides Update on Generex Oral-lyn™ Clinical & Regulatory Program
3. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
4. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
5. Chandler Chicco Companies Acquires Haas & Health Partner Public Relations and SanCom Creative Communication Solutions, Creating Unrivalled Healthcare Communication Capability in Germany
6. Generex Subsidiary Antigen Express Provides Update on AE37 Cancer Vaccines Clinical & Regulatory Strategy
7. Fifth Cycle of Probiotics & Microbiota Research Grant Announced
8. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
9. Aeras and CNBG Sign Agreement on Tuberculosis Vaccine R&D
10. Ikaria® to Present at 14th Annual BIO CEO & Investor Conference
11. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... 2013 Smarter Security, Inc., provider of ... announced that Genzyme, a Sanofi company and leading biotech ... CL for a multi-use facility in the United States. ... Genzyme buildings, this latest order underscores the satisfaction and ... detection device improving doorway access control. , ...
(Date:5/21/2013)... FL (PRWEB) May 21, 2013 Many ... breakouts as contributor to acne. Recently physicians from ... of mental stress on the skin, and suggested using ... help reduce the chemicals produced from stress that cause ... from the negative feelings acne brings about, stress causes ...
(Date:5/21/2013)...  Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of ... diseases, announced today that Jeffrey Riley , ... LLP MicroCap Conference on Thursday, May 30, 2013 in ... Hotel. Mr. Riley is scheduled to present at 10:00 a.m. ... presentation can be accessed by logging onto the web at ...
(Date:5/21/2013)... Minneapolis, MN (PRWEB) May 21, 2013 ... a patented automatic colony counter, announced today that they ... four products , the IncuCount, IntelliCount, InCount and ... price and sophistication are especially useful in food microbiology ... been given an updated look. A bright white ...
Breaking Biology Technology:Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Synthetic Biologics to Present at the 2nd Annual Marcum LLP MicroCap Conference 2Revolutionary Science Announces New Automatic and Manual Colony Counting Products 2
... Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today ... review, the Company is initiating a U.S.,Phase ... REOLYSIN(R) in,combination with paclitaxel and carboplatin in ... K-RAS or EGFR-activated tumours. The Principal,Investigator is ...
... /PRNewswire-FirstCall/ - OncoGenex,Pharmaceuticals, Inc. (NASDAQ: OGXI ... that it has granted to Eagle Pharmaceuticals, ... commercialize TOCOSOL(R),Paclitaxel. Under the terms of the ... from future TOCOSOL Paclitaxel sales and a,percentage ...
... Germany, Sept. 1 ,Boston Scientific Corporation (NYSE: ... its landmark SYNTAX trial comparing percutaneous coronary ... Stent,System to contemporary coronary artery bypass graft ... significant differences,between PCI and CABG in rates ...
Cached Biology Technology:/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 2/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 3/R E P E A T -- Oncolytics Biotech Inc. Announces U.S. Phase 2 Combination Clinical Trial for Non-Small Cell Lung Cancer Patients with K-RAS or EGFR-Activated Tumours/ 4OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 2OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 2Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 3Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 4Landmark SYNTAX Trial Reports Comparable Safety Outcomes for Complex Patients Treated With TAXUS(R) Express2(TM) Stents or Bypass Surgery 5
(Date:5/21/2013)... 21, 2013 Royal Philips Electronics (NYSE: PHG, ... first portable ultrasound with Philips, industry leading Live 3D ... CX50 xMATRIX with available Live 3D TEE and ICE ... at the EuroPCR, official meeting for the European Association ... Since its launch in 2012, Philips CX50 xMATRIX has ...
(Date:5/21/2013)... the way genes function without changing the underlying ... blood of pregnant women during any trimester, potentially ... the weeks after giving birth, and an opportunity ... findings of the small study involving 52 pregnant ... Molecular Psychiatry . , "Postpartum depression can be ...
(Date:5/20/2013)... also commonly resistant to antimicrobial substances made by ... mBio , the online open-access journal of ... and host antimicrobials LL-37 and lysozyme, which help ... that patients with life-threatening multi-drug resistant infections are ... is a last-line drug for treating several kinds ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... "Basic science and clinical medicine move at different pace ... strategies to manage cancer patients. We need to efficiently translate ... in the clinic." Sherene Loi and Fabrice Andr, ... four major areas: , Molecular pathology, the roots ...
... award-winning research project, funded by the British Heart Foundation (BHF), ... how doctors predict a patient,s risk of having a heart ... a BHF Centre of Research Excellence, in collaboration with the ... of combining PET and CT scanning to image the disease ...
... Mass. A team of kinesiology researchers led by ... recently received a 2.5-year, $975,000 grant through the Navy ... study how the average 100-lb. equipment load carried by ... affects their survivability, likelihood of injury and ability to ...
Cached Biology News:Fourth IMPAKT Breast Cancer Conference 2Fourth IMPAKT Breast Cancer Conference 3Scientists develop new technique that could improve heart attack prediction 2Kinesiology team gets $975,000 Defense grant to study effects of heavy loads on soldiers 2
... coating using advanced automated high throughput microplate processing equipment that ... also accommodate virtually any lot size of the following formats ... 8 and 12 well strips, ... 384 well microplate, ...
...
... Mynox is the first biological ... killing them, and not just ... the only anti-mycoplasma agent that ... virus stocks directly. The cytotoxicity ...
Mynox is intended for research use only. Mynox is used for the elimination of Mycoplasma and Acholeplasma in cell and virus cultures, and other biologicals....
Biology Products: